Preprint Brief Report Version 1 Preserved in Portico This version is not peer-reviewed

Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Non-infected Patients

Sonia Algarate
† ,
Laura Serrano
,
Jessica Bueno
,
Beatriz Herrero-Cortina
ORCID logo ,
Elena Alvarado
,
María T. González-Barriga
,
María Ducons
,
Jesica Montero-Marco
,
Sara Arnal
,
Beatriz Acha
,
María Riesgo
,
Ana Taboada
,
Pilar Sanz-Burillo
,
Cristina Yuste
ORCID logo ,
Rafael Benito
*,† ORCID logo
†
These authors contributed equally to this work.
Version 1 : Received: 29 May 2023 / Approved: 31 May 2023 / Online: 31 May 2023 (11:18:10 CEST)

A peer-reviewed article of this Preprint also exists.

Algarate, S.; Serrano, L.; Bueno, J.; Herrero-Cortina, B.; Alvarado, E.; González-Barriga, M.T.; Ducons, M.; Montero-Marco, J.; Arnal, S.; Acha, B.; Riesgo, M.; Taboada, A.; Sanz-Burillo, P.; Yuste, C.; Benito, R.; on behalf of the RIPOVAC Study Group. Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers. Int. J. Mol. Sci. 2023, 24, 10713. Algarate, S.; Serrano, L.; Bueno, J.; Herrero-Cortina, B.; Alvarado, E.; González-Barriga, M.T.; Ducons, M.; Montero-Marco, J.; Arnal, S.; Acha, B.; Riesgo, M.; Taboada, A.; Sanz-Burillo, P.; Yuste, C.; Benito, R.; on behalf of the RIPOVAC Study Group. Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers. Int. J. Mol. Sci. 2023, 24, 10713.

Abstract

Our aim was to evaluate the immune response of healthcare workers included in the RIPOVAC study, after receiving a booster dose (third dose), in terms of intensity and persistence of induced antibodies. In the second phase of RIPOVAC study, between December 2021 and January 2022, eight months after the second dose, 389 voluntary, immunocompetent, non-pregnant healthcare workers received a booster dose of SARS-CoV-2 vaccine, and a serum sample was obtained. Two groups of patients were established: with and without previous SARS-CoV-2 infection. In order to quantify anti-S1 IgG (AU/mL) we used CMIA (Abbott). All the health workers were anti-S IgG positive 8 months after receiving the booster dose of the vaccine, with a mean of 17040 AU/mL. In 53 patients without previous infection, antibody levels had increased by a mean of 10762 AU/mL. This figure is 7 times higher than the one produced after the second dose (1506 AU/mL). The booster dose produces a robust elevation of the antibody level, which persists at 8 months with levels up to values significantly higher than those reached after the second dose, that allow to predict a persistence of more than one year. The study demonstrates the efficacy of the booster dose of anti-SARS-CoV-2 vaccines.

Keywords

SARS-CoV-2; booster vaccine; post-vaccine IgG antibody persistence

Subject

Medicine and Pharmacology, Immunology and Allergy

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.